Heiko Hermeking

Prof. Dr. Heiko Hermeking

Experimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University Munich, Munich, Germany
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2009 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
Heiko HermekingHeiko Hermeking
Heiko Hermeking

18 March 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Matjaz RokavecMatjaz Rokavec
Matjaz Rokavec
MÖMeryem Gülfem Öner
Meryem Gülfem Öner
HLHuihui Li
Huihui Li
RJRene Jackstadt
Rene Jackstadt
LJLongchang Jiang
Longchang Jiang
Heiko HermekingHeiko Hermeking
Heiko Hermeking
Members of the miR-34 family are induced by the tumor suppressor p53 and are known to inhibit epithelial-to-mesenchymal transition (EMT) and therefore presumably suppress the early phases of metastasis. Here, we determined that exposure of human colorectal cancer (CRC) cells to the cytokine IL-6 activates the oncogenic STAT3 transcription factor, which directly represses the MIR34A gene via a conserved STAT3-binding site in the first intron. Repression of MIR34A was required for IL-6–induced EMT and invasion. Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6–dependent STAT3 activation, as a conserved, direct miR-34a target. The resulting IL-6R/STAT3/miR-34a feedback loop was present in primary colorectal tumors as well as CRC, breast, and prostate cancer cell lines and associated with a mesenchymal phenotype. An active IL-6R/STAT3/miR-34a loop was necessary for EMT, invasion, and metastasis of CRC cell lines and was associated with nodal and distant metastasis in CRC patient samples. p53 activation in CRC cells interfered with IL-6–induced invasion and migration via miR-34a–dependent downregulation of IL6R expression. In Mir34a-deficient mice, colitis-associated intestinal tumors displayed upregulation of p-STAT3, IL-6R, and SNAIL and progressed to invasive carcinomas, which was not observed in WT animals. Collectively, our data indicate that p53-dependent expression of miR-34a suppresses tumor progression by inhibiting a IL-6R/STAT3/miR-34a feedback loop.

17 August 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Heiko HermekingHeiko Hermeking
Heiko Hermeking

9 May 2014 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
Matjaz RokavecMatjaz Rokavec
Matjaz Rokavec
HLHuihui Li
Huihui Li
LJLongchang Jiang
Longchang Jiang
Heiko HermekingHeiko Hermeking
Heiko Hermeking
The tumor suppressor p53 is one of the most frequently mutated genes in human cancers. MicroRNAs (miRNAs) are small non-protein coding RNAs that regulate gene expression on the post-transcriptional level. Recently, it was shown that p53 regulates the expression of several miRNAs, thereby representing an important mechanism of p53 signaling. Several independent studies identified the members of the miR-34 family as the most prevalent p53-induced miRNAs. miR-34s are frequently silenced in variety of tumor entities, suggesting that they are important tumor suppressors. Indeed, ectopic expression of miR-34s inhibits proliferation, epithelial to mesenchymal transition, migration, invasion, and metastasis of various cancer cell entities. Moreover, delivery or re-expression of miR-34 leads to notable repression of tumor growth and metastasis in cancer mouse models, and may therefore represent an efficient strategy for future cancer therapeutics. Besides their crucial functions in cancer, members of the miR-34 family also play important roles in spermatogenesis, stem cell differentiation, neuronal development, aging, and cardiovascular functions. Consequently, miR-34 has also been implicated in various non-cancerous diseases, such as brain disorders, osteoporosis, and cardiovascular complications.

12 January 2011 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
MVMarkus Vogt
Markus Vogt
JMJohanna Munding
Johanna Munding
MGMartha Grüner
Martha Grüner
SLSven-Thorsten Liffers
Sven-Thorsten Liffers
BVBerlinda Verdoodt
Berlinda Verdoodt
Heiko HermekingHeiko Hermeking
Heiko Hermeking

21 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AMAntje Menssen
Antje Menssen
PHPer Hydbring
Per Hydbring
KKKarsten Kapelle
Karsten Kapelle
JVJörg Vervoorts
Jörg Vervoorts
JDJoachim Diebold
Joachim Diebold
Heiko HermekingHeiko Hermeking
Heiko Hermeking
Silent information regulator 1 (SIRT1) represents an NAD + -dependent deacetylase that inhibits proapoptotic factors including p53. Here we determined whether SIRT1 is downstream of the prototypic c- MYC oncogene, which is activated in the majority of tumors. Elevated expression of c-MYC in human colorectal cancer correlated with increased SIRT1 protein levels. Activation of a conditional c- MYC allele induced increased levels of SIRT1 protein, NAD + , and nicotinamide-phosphoribosyltransferase ( NAMPT ) mRNA in several cell types. This increase in SIRT1 required the induction of the NAMPT gene by c-MYC. NAMPT is the rate-limiting enzyme of the NAD + salvage pathway and enhances SIRT1 activity by increasing the amount of NAD + . c-MYC also contributed to SIRT1 activation by sequestering the SIRT1 inhibitor deleted in breast cancer 1 (DBC1) from the SIRT1 protein. In primary human fibroblasts previously immortalized by introduction of c-MYC, down-regulation of SIRT1 induced senescence and apoptosis. In various cell lines inactivation of SIRT1 by RNA interference, chemical inhibitors, or ectopic DBC1 enhanced c-MYC-induced apoptosis. Furthermore, SIRT1 directly bound to and deacetylated c-MYC. Enforced SIRT1 expression increased and depletion/inhibition of SIRT1 reduced c-MYC stability. Depletion/inhibition of SIRT1 correlated with reduced lysine 63-linked polyubiquitination of c-Myc, which presumably destabilizes c-MYC by supporting degradative lysine 48-linked polyubiquitination. Moreover, SIRT1 enhanced the transcriptional activity of c-MYC. Taken together, these results show that c-MYC activates SIRT1, which in turn promotes c-MYC function. Furthermore, SIRT1 suppressed cellular senescence in cells with deregulated c-MYC expression and also inhibited c-MYC–induced apoptosis. Constitutive activation of this positive feedback loop may contribute to the development and maintenance of tumors in the context of deregulated c-MYC.